Comparison of Synthetic High Density Lipoprotein (HDL) Contrast Agents for MR Imaging of Atherosclerosis
- 20 April 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 20 (5) , 937-943
- https://doi.org/10.1021/bc800520d
Abstract
Determining arterial macrophage expression is an important goal in the molecular imaging of atherosclerosis. Here, we compare the efficacy of two synthetic, high density lipoprotein (HDL) based contrast agents for magnetic resonance imaging (MRI) of macrophage burden. Each form of HDL was labeled with gadolinium and rhodamine to allow MRI and fluorescence microscopy. Either the 37 or 18 amino acid peptide replaced the apolipoprotein A-I in these agents, which were termed 37pA-Gd or 18A-Gd. The diameters of 37pA-Gd and 18A-Gd are 7.6 and 8.0 nm, respectively, while the longitudinal relaxivities are 9.8 and 10.0 (mM s)−1. 37pA has better lipid binding properties. In vitro tests with J774A.1 macrophages proved the particles possessed the functionality of HDL by eliciting cholesterol efflux and were taken up in a receptor-like fashion by the cells. Both agents produced enhancements in atherosclerotic plaques of apolipoprotein E knockout mice of ∼90% (n = 7 per agent) and are macrophage specific as evidenced by confocal microscopy on aortic sections. The half-lives of 37pA-Gd and 18A-Gd are 2.6 and 2.1 h, respectively. Despite the more favorable lipid interactions of 37pA, both agents gave similar, excellent contrast for the detection of atherosclerotic macrophages using MRI.Keywords
This publication has 29 references indexed in Scilit:
- Nanocrystal Core High-Density Lipoproteins: A Multimodality Contrast Agent PlatformNano Letters, 2008
- An ApoA‐I Mimetic Peptide High‐Density‐Lipoprotein‐Based MRI Contrast Agent for Atherosclerotic Plaque Composition DetectionSmall, 2008
- Nanoparticle PET-CT Imaging of Macrophages in Inflammatory AtherosclerosisCirculation, 2008
- In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administrationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRIProceedings of the National Academy of Sciences, 2007
- Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiformeInternational Journal of Pharmaceutics, 2007
- Macrophage Uptake of Core−Shell Nanoparticles Surface Modified with Poly(ethylene glycol)Langmuir, 2006
- Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1Journal of Lipid Research, 2006
- Recombinant HDL-Like Nanoparticles: A Specific Contrast Agent for MRI of Atherosclerotic PlaquesJournal of the American Chemical Society, 2004
- Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance.Journal of Clinical Investigation, 1983